Search results for "ALZHEIMER’S DISEASE"

showing 10 items of 120 documents

Immunological and immunogenetic markers in sporadic Alzheimer’s disease

2006

Background: Common polymorphisms of genes controlling inflammation-modulating cytokines and acute-phase proteins which play important roles in the pathogenesis of Alzheimer''s disease (AD) have been shown to be associated with AD. Aims: The immunological and immunogenetic markers potentially useful for the AD risk evaluation and diagnosis are briefly reviewed. Conclusion: The state-of-the-art of immunological and immunogenetic markers of AD indicates that new tools and strategies are necessary to identify gene products useful as diagnostic tools.

AgingDiseaseImmunogeneticsDiagnostic toolsProteomicsPathogenesisApolipoproteins EAlzheimer DiseaseHumansMedicineOligonucleotide Array Sequence AnalysisInflammationAlzheimer’s disease cytokines immunogenetics inflammation proteomicsPolymorphism GeneticGeriatrics gerontologybusiness.industryDNARisk evaluationGene Expression RegulationPositron-Emission TomographyImmunologyCytokinesMicrogliaGeriatrics and GerontologybusinessBiomarkersAcute-Phase ProteinsAging Clinical and Experimental Research
researchProduct

Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment

2009

Alzheimer's disease (AD) is the most common type of dementia in the elderly. Products of oxidative and nitrosative stress (OS and NS, respectively) accumulate with aging, which is the main risk factor for AD. This provides the basis for the involvement of OS and NS in AD pathogenesis. OS and NS occur in biological systems due to the dysregulation of the redox balance, caused by a deficiency of antioxidants and/or the overproduction of free radicals. Free radical attack against lipids, proteins, sugars and nucleic acids leads to the formation of bioproducts whose detection in fluids and tissues represents the currently available method for assessing oxidative/nitrosative damage. Post-mortem …

AgingPathologymedicine.medical_specialtyFree RadicalsAlzheimer’s disease Mild cognitive impairment Free radicals Nitrosative stress Oxidative stressBioenergeticsDiseaseOxidative phosphorylationmedicine.disease_causeBiochemistryPathogenesisAlzheimer DiseaseHumansMedicineDementiaMolecular BiologyFree-radical theory of agingbusiness.industryMetabolismmedicine.diseaseOxidative StressNeurologyImmunologySettore MED/26 - NeurologiaCognition DisordersReactive Oxygen SpeciesbusinessBiomarkersOxidative stressBiotechnology
researchProduct

The Impact of COVID-19 Quarantine on Patients With Dementia and Family Caregivers: A Nation-Wide Survey

2021

IntroductionPrevious studies showed that quarantine for pandemic diseases is associated with several psychological and medical effects. The consequences of quarantine for COVID-19 pandemic in patients with dementia are unknown. We investigated the clinical changes in patients with Alzheimer’s disease and other dementias, and evaluated caregivers’ distress during COVID-19 quarantine.MethodsThe study involved 87 Italian Dementia Centers. Patients with Alzheimer’s Disease (AD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementia (FTD), and Vascular Dementia (VD) were eligible for the study. Family caregivers of patients with dementia were interviewed by phone in April 2020, 45 days after …

AgingPediatricsmedicine.medical_specialtyCognitive Neurosciencelcsh:RC321-57103 medical and health sciences0302 clinical medicinemental disordersAlzheimer’s disease BPSD caregiver burden COVID-19 dementia quarantinemedicineDementiaBPSD030212 general & internal medicineVascular dementialcsh:Neurosciences. Biological psychiatry. NeuropsychiatryAlzheimer’s disease; BPSD; caregiver burden; COVID-19; dementia; quarantineDepression (differential diagnoses)Original ResearchM-PSI/05 - PSICOLOGIA SOCIALEMED/26 - NEUROLOGIAcaregiver burdenDementia with Lewy bodiesFamily caregiversbusiness.industryquarantineCOVID-19Odds ratiomedicine.diseaseSettore MED/26 - NEUROLOGIADistressMED/17 - MALATTIE INFETTIVEbusinessAlzheimer’s disease030217 neurology & neurosurgeryNeuroscienceFrontotemporal dementiadementia
researchProduct

The implicit motor learning use as a therapeutic tool in frail elderly people

2016

To write, take, walk, talk is a part of our daily. Our motor ability is used to change depending on our environment and our skill, acquired thanks to our experience, learnings, and according to our age. We strive to find optimal solutions, to be more performants, more efficient. But we must be able to discern to act well and act to better discern. This « perception-action » coupling is the basis of the organization of motor control. Human can discern through several sensory systems (Visual, auditory, proprioceptive) intrinsic informations, coming from his own body, and extrinsic informations, from his environment. All of these informations are in the service of the movement and actions of d…

AgingSerious gamesFrailtyFragilitéCouplage perception-actionMaladie d’AlzheimerVieillissementVirtual realityApprentissagePerception-action couplingRéalité virtuelle[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Learning[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Alzheimer’s disease
researchProduct

Alzheimer’s disease and infections, where we stand and where we go

2014

Editorial Alzheimer’s disease (AD) is a progressive neurological disorder, which represents the most common form of dementia, one of the major causes of disability in later life. Age is the greatest risk factor for AD, which typically affects people aged 65 years and over, with an age-standardised prevalence of 4.4 [1]. However, AD is not a normal part of ageing and advanced age alone does not justify the disease. Several pathways have been implicated in AD pathophysiology, the most described is the neurodegenerative one, which lead to the brain accumulation of beta-amyloid and neurofibrillary tangles, aggregations of hyperphosphorylated tau protein, macroscopically resulting in brain atrop…

AgingTraumatic brain injuryImmunologyTau proteinperiodontal diseaseDiseaseInfectionsBioinformaticsAtrophyAlzheimer'MedicineDementiaRisk factorAlzheimer's; infections; herpes viruses; periodontal disease; infectionInflammationSettore MED/04 - Patologia Generalebiologybusiness.industryVascular diseaseHerpes virusesOdds ratiomedicine.diseaseinfectionAgeingEditorialImmunologybiology.proteinherpes viruseSettore MED/26 - NeurologiabusinessAlzheimer’s diseaseImmunity & Ageing
researchProduct

Postprandial Hyperglycemia Is Associated With White Matter Hyperintensity and Brain Atrophy in Older Patients With Type 2 Diabetes Mellitus

2018

Type 2 diabetes mellitus is associated with neurodegeneration and cerebrovascular disease. However, the precise mechanism underlying the effects of glucose management on brain abnormalities is not fully understood. The differential impacts of glucose alteration on brain changes in patients with and without cognitive impairment are also unclear. This cross-sectional study included 57 older type 2 diabetes patients with a diagnosis of Alzheimer's disease (AD) or normal cognition (NC). We examined the effects of hypoglycemia, postprandial hyperglycemia and glucose fluctuations on regional white matter hyperintensity (WMH) and brain atrophy among these patients. In a multiple regression analysi…

Agingmedicine.medical_specialtyendocrine system diseasesCognitive Neuroscience030209 endocrinology & metabolismDiseaseType 2 diabetesHypoglycemialcsh:RC321-57103 medical and health sciences0302 clinical medicineAtrophyDiabetes mellitusInternal medicineMedicineCognitive declinepostprandial hyperglycemialcsh:Neurosciences. Biological psychiatry. Neuropsychiatrybusiness.industrywhite matter hyperintensityType 2 Diabetes Mellitusmedicine.diseasePostprandialdiabetes mellitusCardiologybusinessAlzheimer’s diseasebrain atrophy030217 neurology & neurosurgeryFrontiers in Aging Neuroscience
researchProduct

Targeting Alzheimer’s disease with multimodal polypeptide-based nanoconjugates

2021

LRP1-targeted St-Cl–polyglutamate conjugates as multivalent neuroprotective/neurotrophic therapeutics for Alzheimer’s disease.

Alzheimer’s disease (AD)Mice TransgenicNanoconjugatesHippocampal formationHippocampusNeuroprotectionAD treatmentMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAlzheimer DiseaseBisdemethoxycurcuminAnimalsOlfactory memoryResearch Articles030304 developmental biology0303 health sciencesAmyloid beta-PeptidesMultidisciplinaryPolyglutamatebiologySciAdv r-articlesLife Sciences3. Good healthOlfactory bulbDisease Models AnimalApplied Sciences and Engineeringchemistrybiology.proteinNeuroscience030217 neurology & neurosurgeryNanoconjugatesResearch ArticleNeurotrophinScience Advances
researchProduct

Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer’s Disease from Other Neurological Disorders

2022

Recently, the synaptic proteins neurogranin (Ng) and α-synuclein (α-Syn) have attracted scientific interest as potential biomarkers for synaptic dysfunction in neurodegenerative diseases. In this study, we measured the CSF Ng and α-Syn concentrations in patients affected by AD (n = 69), non-AD neurodegenerative disorders (n-AD = 50) and non-degenerative disorders (n-ND, n = 98). The concentrations of CSF Ng and α-Syn were significantly higher in AD than in n-AD and n-ND. Moreover, the Aβ42/Ng and Aβ42/α-Syn ratios showed statistically significant differences between groups and discriminated AD patients from n-AD patients, better than Ng or α-Syn…

Alzheimer’s disease; biomarkers; neurogranin; α-synucleinAmyloid beta-PeptidesneurograninOrganic ChemistrybiomarkersNeurodegenerative Diseasestau ProteinsGeneral MedicineCatalysisSettore MED/01 - Statistica MedicaComputer Science ApplicationsInorganic Chemistryα-synucleinAlzheimer DiseaseFluorodeoxyglucose F18alpha-SynucleinHumansCognitive DysfunctionSettore MED/26 - NeurologiaPhysical and Theoretical ChemistryAlzheimer’s diseaseMolecular BiologySpectroscopyInternational Journal of Molecular Sciences; Volume 23; Issue 18; Pages: 10831
researchProduct

Lipofuscin Hypothesis of Alzheimer’s Disease

2011

The primary culprit responsible for Alzheimer’s disease (AD) remains unknown. Aβ protein has been identified as the main component of amyloid of senile plaques, the hallmark lesion of AD, but it is not definitively established whether the formation of extracellular Aβ deposits is the absolute harbinger of the series of pathological events that hit the brain in the course of sporadic AD. The aim of this paper is to draw attention to a relatively overlooked age-related product, lipofuscin, and advance the hypothesis that its release into the extracellular space following the death of neurons may substantially contribute to the formation of senile plaques. The presence of intraneuronal Aβ, sim…

Aβ proteinNeurofibrillary tanglesAmyloidAmyloidCognitive Neurosciencelcsh:Geriatricslcsh:RC346-429LipofuscinLipofuscinLesionExtracellularMedicineOriginal Research ArticleSenile plaquesPathologicallcsh:Neurology. Diseases of the nervous systembusiness.industryMacular degenerationAlzheimer's diseaseMacular degenerationmedicine.diseaseBiochemistry of Alzheimer's diseaselcsh:RC952-954.6Psychiatry and Mental healthmedicine.symptombusinessAlzheimer’s diseaseNeuroscienceDementia and Geriatric Cognitive Disorders Extra
researchProduct

Involvment of docosanoïc acid (C22=0), and of very long chain fatty acids (tetracosanoïc acid (C24=0), hexacosanoïc acid (C26=0) in Alzheimer's disea…

2013

In the brain and in the plasma of patients with Alzheimer’s disease (AD), marked accumulation of C22:0 and of very long chain fatty acids (C24:0 ; C26:0) have been reported. Important decreases of docosahexaenoic acid (DHA; C22:6 n-3) have also been described as well as quantitative and qualitative modifications of plasmalogens. Altogether, these lipid modifications suggest an implication of peroxisomal metabolism disorders in the physiopathology of AD. Therefore, the biological activities of C22:0, C24:0 and C26:0 have been studied on human neuronal cells SK-N-BE. On these cells, the lipotoxicity of fatty acids (C22:0, C24:0 and C26:0) leads to various cellular modifications: topographical…

Biomarqueurs[SDV.SA] Life Sciences [q-bio]/Agricultural sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyHexacosanoic acid (C26:0)Acide hexacosanoique (C26:0)Souris transgénique APP PS1 ΔE9Transgenic mouse APP PS1 ΔE9PeroxisomeMaladie d’AlzheimerAcides gras à très longue chaîneVery long chain fatty acidsLipotoxicitéTetracosanoic acid (C24:0)Docosanoic acid (C22:0)DemenciaDémencesAcide tétracosanoique (C24:0)PeroxysomeAcide docosanoIque (C22:0)Alzheimer’s diseaseBiomarkersLipotoxicity
researchProduct